Pediatr. pro Praxi, 2007; 2: 88-91

Rotaviral infection, current possibilities of the vaccination

doc. MUDr. Petr Pazdiora CSc
Ústav epidemiologie LF UK, Plzeň

Rotaviruses cause annually 111–125 million of illnesses leading to 0.5–1 million of deaths. As many as 2,837 sporadic cases and 820 cases from 23 outbreaks were reported to the Public Health Service in 2006 in the Czech Republic. No case was lethal. In 2006 4,815 rotavirus infection were laboratory confirmed in 80 laboratories of the Czech Republic. Specific morbidity among children under 3 years calculated on the laboratory data was 792 cases/100,000 population/year; among children under 5 years it was 697/100,000.

With registration of 2 new vaccines (Rotarix, RotaTeq) it is realistic to gradually fulfil extended WHO immunisation programme that intends to introduce vaccinations against these infections. Both vaccines despite different properties confirm a high level of imunogenicity and protection. They are gradually introduced to the market not only in the European countries but also in other countries.

Keywords: Rotarix, RotaShield, RotaTeq, rotavirus infection, vaccination

Published: May 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pazdiora P. Rotaviral infection, current possibilities of the vaccination. Pediatr. praxi. 2007;8(2):88-91.
Download citation

References

  1. Berner R, Schumacher RF, Hameister S, et al. Occurrence and impact of community-acquired and nosocomial rotavirus infections - a hospital-based study over 10 y. A. Paediatr 1999; 88: 48-52. Go to original source... Go to PubMed...
  2. CDC: Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory committee on immunization practices (ACIP). Morbid Mortal Wkl Rep 1999; 48: 24.
  3. FDA: FDA issues information update on rotavirus vaccine. RotaFlash 2007; February 14.
  4. Orenstein WA, Hadler S, Kuritsky JN, et al. Rotavirus vaccines-from licensure to disease reduction. J Infect Dis 1996; 174: 118-124. Go to original source... Go to PubMed...
  5. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9: 565-572. Go to original source... Go to PubMed...
  6. Pazdiora P. Rotavirové infekce. Přednáška, IPVZ Praha, 4. 4. 2006.
  7. Pazdiora P. Diagnostika rotavirových infekcí v r. 2004, jejich základní charakteristiky v letech 1998-2004 v ČR. Epidem Mikrobiol Imunol 2006; 55: 32-36.
  8. Rendi-Wagner P, Kundi M, Mikolasek A, et al. Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wien Klin Wochenschr 2006; 118: 280-285. Go to original source... Go to PubMed...
  9. Rheingans RD, Heylen J, Giaquinto C. Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense? Pediatr Infect Dis J 2006; 25: 48-55. Go to original source... Go to PubMed...
  10. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354: 11-22. Go to original source... Go to PubMed...
  11. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication fot the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15: 26-56. Go to original source... Go to PubMed...
  12. Soriano-Gabarró M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavitus disease in Europe: time for effective prevention? Pediatr Infect Dis J 2006; 25: 7-11. Go to original source... Go to PubMed...
  13. Souhrn SPC. EU/1/05/330/001/004. Souhrn údajů o přípravku ROTARIX. Datum revize textu 21. 2. 2006.
  14. Souhrn SPC. EU/1/06/338/001-002. Souhrn údajů o přípravku ROTATEQ. Datum revize textu 27. 6. 2006.
  15. Táborská J, Pazdiora P. Rotavirus jako nejčastější původce průjmů u dětí. Pediatrie pro praxi 2005; 6: 135-140.
  16. Van Damme P, Van der Wielen M, Ansaldi F, et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis 2006; 6: 805-812. Go to original source... Go to PubMed...
  17. Vesikari T, Joensuu J, Baer M, et al. Concurent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphteria-pertussis-tetanusHaemophilus influenzae beta-inactivated polio and hepatitis B vaccines. A Paediatr 1999; 88: 513-520. Go to original source... Go to PubMed...
  18. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortanat rotavirus vaccine. N Engl J Med 2006; 354: 23-33. Go to original source... Go to PubMed...
  19. Watson B. Vaccines in the pipeline-an overview. Infect Med 2001; 18: 27-32.




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.